Clinical significance of Talin-1 and HER-2 status in different types of gastric carcinoma
Creators: name: Hashemi, Farideh
name: Tajik, Fatemeh
name: Zanjani, Leili Saeednejad
name: Manshadi, Masoumeh Dehghan
name: Safaei, Sadegh
name: Babaheidarian, Pegah
name: Fattahi, Fahimeh
name: Ghods, Roya
name: Madjd, Zahra
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Chemical Sciences not elsewhere classified
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences

description: Talin-1 (TLN1) is crucial in cell migration, metastasis, and cancer development. This study evaluated Talin-1 expression and its clinical significance in gastric cancer (GC), along with human epidermal growth factor receptor-2 (HER-2) expression and its correlation with Talin-1. Bioinformatics analysis assessed the potential prognostic value of Talin-1 and HER-2 in GC patients. The study included 223 GC patients (Signet Ring Cells and Intestinal subtypes) and 29 non-malignant tissue samples. Immunohistochemistry (IHC) on tissue microarray slides evaluated Talin-1 and HER-2 expression and clinical significance. Receiver operating characteristic (ROC) curves assessed their diagnostic value. Bioinformatics identified Talin-1 as a potential prognostic factor and HER-2 as an oncogene in GC. Talin-1 and HER-2 expression increased in SRC-type GC samples compared to non-malignant tissues. High cytoplasmic Talin-1 expression inversely correlated with tumor expansion and invasion in SRC-type GC. Increased HER-2 expression positively correlated with metastasis. ROC curves showed significant diagnostic values for both proteins. Higher cytoplasmic Talin-1 expression is associated with less invasive tumor behavior, while increased membranous HER-2 expression is associated with metastasis in SRC-type GC. These findings suggest potential use in assessing diagnosis and screening high-risk cancer patients, particularly those with SRC-type GC. Gastric cancer (GC) is a leading cause of cancer‑related deaths, often diagnosed at advanced stages, complicating treatment. This study highlights Talin‑1 as a potential prognostic marker in signet ring cell (SRC) subtype GC, where higher cytoplasmic expression is linked to reduced invasiveness. In contrast, increased membranous HER‑2 expression correlates with metastasis, emphasizing its role as an oncogene.These findings suggest that Talin‑1 could aid in patient stratification for less aggressive tumors, while HER‑2 status may guide targeted therapies. The combined assessment of Talin‑1 and HER‑2 could enhance diagnostic accuracy and risk assessment, contributing to improved patient management and outcomes in gastric cancer. Gastric cancer (GC) is a leading cause of cancer‑related deaths, often diagnosed at advanced stages, complicating treatment. This study highlights Talin‑1 as a potential prognostic marker in signet ring cell (SRC) subtype GC, where higher cytoplasmic expression is linked to reduced invasiveness. In contrast, increased membranous HER‑2 expression correlates with metastasis, emphasizing its role as an oncogene. These findings suggest that Talin‑1 could aid in patient stratification for less aggressive tumors, while HER‑2 status may guide targeted therapies. The combined assessment of Talin‑1 and HER‑2 could enhance diagnostic accuracy and risk assessment, contributing to improved patient management and outcomes in gastric cancer.